Israel's Teva to pay $1.6b for patent infringement

Teva Pharmaceuticals will compensate Pfizer and Takeda for infringing the patent on reflux treatment Protonix.

By SHIRI HABIB-VALDHORN, GLOBES' CORRESPONDENT
June 12, 2013 20:18
1 minute read.
Teva Pharmaceutical plant is seen in Jerusalem

Teva 311. (photo credit: REUTERS/Ronen Zvulun)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Teva Pharmaceutical Industries will pay Pfizer Inc. and Nycomed (now a unit of Japan's Takeda Pharmaceutical Co) $1.6 billion to settle the patent infringement suit over its "at risk" launch of the generic version of Pfizer's Protonix, for the treatment of reflux, in the US ten years ago.

When a generic company makes an at-risk launch of a drug, before the legal proceedings are completed, the compensation can reach three times the lost profits of the maker of the brand drug.

In addition, India's Sun Pharmaceutical Industries Ltd. (which controls Taro Pharmaceutical Industries Ltd.) will also pay $550 million to Pfizer and Takeda. Pfizer and Takeda will divide the proceeds of the settlement 64%/36%.

Under the settlement, Teva will pay $800 million this year, and the rest through October 2014. Teva has already made a $670 million write-off on Protonix, and it estimated the maximum write-off at $1.4 billion.

The settlement came after the US District Court for the District of New Jersey ruled in Pfizer favor in the case in April 2010, and just after the start of the trial to determine damages. As part of the settlement, both Teva and Sun Pharmaceuticals have admitted that their sales of generic pantoprazole infringed the patent that was held valid by the court.

Protonix had $1.9 billion in annual sales before the launch of the generic versions, after which sales plummeted. Teva said that in the 12 months through January 2011 sales of its generic Protonix totaled $1.1 billion.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Cookie Settings